You just read:

Aprea Therapeutics Announces First Patients Enrolled in Phase II Clinical Study of APR-246 for the Treatment of High-Grade Serous Ovarian Cancer

News provided by

Aprea Therapeutics AB

10 Oct, 2016, 03:00 ET